References
- Bast R C, Jr, Klug T L, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl I Med 1983; 309: 883–887
- Zanaboni F, Vergadoro F, Presti M, et al. Tumor antigen CA125 as a marker of ovarian epithelial carcinoma. Gynecol Oncol 1987; 28: 61–67
- Crombach G, Zippel H H, Wurz H. Clinical significance of cancer antigen 125 (CA125) in ovarian cancer. Cancer Detect Prevent 1985; 8: 135–139
- Krebs H B, Gopterud D R, Kilpatrick S J, et al. Role of Ca 125 as a tumor marker in ovarian carcinoma. Obstet Gynecol 1986; 67: 472–477
- Berek I S, Knapp R C, Malkasian G D, et al. CA125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986; 67: 685–689
- Stehman F B, Calkins A R, Wass J L, et al. A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer. Gynecol Oncol 1988; 29: 37–42
- Brenner D E, Shaff M I, Jones H W, et al. Abdominopelvic computed tomography: evaluation in patients undergoing second-look laparotomy for ovarian carcinoma. Obstet Gynecol 1985; 65: 715–719
- Finkler N J, Kapnick S J, Griffiths C T, Knapp R C. Elevated CA125 serum levels and epithelial ovarian cancer metastatic to retroperitoneal lymph nodes. Gynecol Oncol 1988; 29: 356–360